

Is it necessary to control the level of estrogen receptor α and β activation in postmenopausal hormone replacement therapy in order to achieve the optimal outcome? (Review)

BAO TING ZHU

Department of Pharmacology, Toxicology and Therapeutics, School of Medicine,
University of Kansas Medical Center, Kansas City, KS 66160, USA

Received November 2, 2007; Accepted November 30, 2007

Abstract. Endogenous estrogens exert an array of biological actions on women, many of which are mediated by the estrogen receptors (ERs) α and β . Results from our recent studies suggest that the human ER α and ER β systems are differentially activated under different physiological conditions. In non-pregnant young women, the ER α system is preferentially activated over the ER β system, mainly by estrone (E₁) and its major oxidative metabolite, 2-hydroxy-E₁. These two estrogens are among the quantitatively major estrogens present in young women, and have approximately 4-fold preferential activity for ER α over ER β . During pregnancy, however, there is a preponderance of activation of ER β over ER α conferred by various pregnancy estrogens such as estriol and other D-ring derivatives of 17 β -estradiol (E₂). These estrogens have an up to 18-fold preference for binding to ER β than for ER α , and some of them are produced in unusually large quantities. Given this new information, it is hypothesized that the estrogens ideal for female hormone replacement therapy (HRT) would be those which produce a hormonal condition mirroring that found in non-pregnant young women rather than in pregnant women. Endogenous estrogen derivatives, such as the sulfated conjugates of E₁, may be among the ideal candidates for achieving this clinical purpose. In comparison, Premarin, the most commonly-used HRT containing a mixture of conjugated estrogens isolated from pregnant mare's urine, is less suitable because several of its estrogenic components can produce a strong preferential overstimulation of the human ER β signaling system.

Correspondence to: Dr Bao Ting Zhu, Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, MS-1018, Room KLSIC-4061, 2146 W. 39th Avenue, Kansas City, KS 66160, USA
E-mail: btzhu@kumc.edu

Abbreviations: ER, estrogen receptor; ER α and ER β , estrogen receptor α and β subtypes; E₁, estrone; E₂, 17 β -estradiol; OH, hydroxy; RBA, relative binding affinity

Key words: hormone replacement therapy, estrogen receptor α and β subtypes, Premarin, estrogens

Contents

1. Introduction
2. Differences in the composition and quantity of endogenous estrogens produced in pregnant and non-pregnant women
3. Differences in the biological activity of pregnancy and non-pregnancy estrogens
4. Biological activity of estrogens contained in Premarin
5. Which estrogens are ideal for postmenopausal hormone replacement therapy?
6. Concluding remarks

1. Introduction

Female hormone replacement therapy (HRT), also commonly called menopausal hormone therapy, is a hormonal treatment for peri- or post-menopausal women undertaken to reduce the discomfort and health problems associated with diminished circulating ovarian hormones (namely, estrogens and progesterone). HRT usually provides a low dose of an estrogen (or a mixture of estrogens), often in combination with a progestin. In the past few decades, the most commonly-used estrogen treatment for HRT has been Premarin, which consists of a mixture of mostly sulfated estrogens isolated from pregnant mare's urine. The hormonal activity of these conjugated estrogens *in vivo* results from their enzymatic hydrolysis and releases biologically active estrogens.

Until a few years ago, the generally-held scientific belief was that 'an estrogen is an estrogen', i.e., that all estrogens exert similar pharmacological actions on the body. However, this dogmatic view has gradually changed over the past decade due, in large part, to the emergence of the following body of new knowledge.

First, it has become known that multiple subtypes of estrogen receptor (ER) exist (1,2). These have very different tissue and cell distribution in the body, and both overlapping and completely different biological functions in different target tissues or cells (1,2).

Second, studies have shown that certain ER agents, such as tamoxifen and raloxifene, can selectively modulate the function of ERs in different target tissues/cells in different ways, serving as ER antagonists in one tissue (such as the breast) but as weak agonists in another (such as bone) (3,4).

Third, certain endogenous estrogens and their metabolic derivatives have very different binding affinities for human ER α and ER β (discussed below) (5). Furthermore, some of the estrogen metabolites that are often selectively formed in certain target cells or formed under unique physiological or pathological conditions can exert very different biological functions that are not necessarily shared by their parent hormone 17 β -estradiol (E₂) (6-8).

Recently, we systematically compared the activity of a large number of endogenous estrogen metabolites, including many of those contained in Premarin, relating to human ER α and ER β (5). We found that while E₂ (perhaps the best-known endogenous estrogen) has nearly the highest, and almost identical, binding affinity for human ER α and ER β , many of its metabolites have widely different preferences for human ER α and ER β activation (5). In addition, it should be noted that the predominant estrogens in pregnant women are very different from those present in non-pregnant ones, and that these estrogens have widely different preferences when it comes to the activation of human ER α and ER β . Based on this information, a new concept is proposed here, one which suggests that differential activation of ER α over ER β may be a crucial factor in achieving optimal clinical outcome in postmenopausal HRT. Recommendations are made as to which types of estrogens would be ideal for human use in menopausal HRT.

2. Differences in the composition and quantity of endogenous estrogens produced in pregnant and non-pregnant women

A large number of endogenous estrogen derivatives are known to be present in humans. Studies have been conducted in the past to determine the human urinary excretion of various estrogens (mostly as conjugates) as a global indicator of the bio-synthesis and metabolism of endogenous estrogens *in vivo* (9,10). Based on our recent data (Table I), it is estimated that the total daily amount of various urinary estrogens excreted from a late-stage pregnant woman is 2-3 orders of magnitude higher than the amount excreted by a non-pregnant woman of the same age group. In addition, the composition of urinary estrogens in pregnant and non-pregnant women is widely different. Representative profiles of various endogenous estrogens found in the urine of pregnant and non-pregnant young women are summarized in Table I.

In the urine samples obtained from non-pregnant young women, the conjugated forms of 2-OH-E₁, followed by 16 α -OH-E₂ (E₃), 16 α -OH-E₁ and E₁ (estrone), are the predominant estrogens. The amount of E₂ and its major metabolites 2-OH-E₂ and 2-methoxy-E₂ was much less than that of E₁ and its corresponding metabolites. The relative composition of the various estrogens in circulation is believed to be comparable to that of urine. The presence of higher levels of E₁ than of E₂ in non-pregnant women is largely attributable to high levels of oxidative 17 β -hydroxysteroid dehydrogenase (17 β -HSD), which catalyzes the facile conversion of E₂ to E₁. The conversion of E₁ to 2-hydroxy-E₁ or E₂ to 2-OH-E₂ is catalyzed by cytochrome P450 enzymes (11-14) and by subsequent *O*-methylation, which forms 2-methoxy-E₁/E₂ is catalyzed by catechol-*O*-methyltransferase (COMT) (7,15).

There is a drastic change in endogenous estrogen composition during pregnancy. E₃ becomes the predominant estrogen and is produced in unusually large quantities. The daily amount of this estrogen (in its conjugated form) released into the urine of late-stage pregnant women is 200-1000 times higher than that of any of the quantitatively major estrogens produced in non-pregnant women. Notably, several other *D*-ring estrogen derivatives, such as 17-epi-E₃, 16-epi-E₃, 16,17-epi-E₃ and estetrol (15 α -OH-E₃), are also produced in readily-detectable quantities during the late stages of pregnancy. These *D*-ring derivatives are usually only present in low or undetectable levels in non-pregnant young women. Similar results have been reported in previous studies (11,12).

In summary, although E₂ is perhaps the best-known endogenous estrogen in humans, it is not the predominant estrogen produced in the body of pregnant women or of non-pregnant women. The major endogenous estrogens that are produced in non-pregnant women are vastly different in quantity and also in composition from those produced in pregnant women.

3. Differences in the biological activity of pregnancy and non-pregnancy estrogens

It is hypothesized that the endogenous estrogens produced in a non-pregnant young woman will exert very different physiological functions than those produced during pregnancy. This hypothesis is supported by the following evidence.

First, as discussed above, the endogenous estrogens formed in non-pregnant women are vastly different in quantity and composition from those produced in pregnant women.

Second, studies in recent years by us and by others have shown that some E₂ derivatives can exert unique biological functions that are not shared by their parent hormone E₂ (reviewed in refs. 6-8,14-16). For instance, a previous study showed that 4-OH-E₂, a well-known hydroxylated metabolite of E₂, has a far stronger blood cholesterol-lowering effect on rats than does E₂ (16), although its uterotrophic activity (16,17) and ER-binding affinity are slightly lower than that of E₂ (5,17). Also, it is well documented that catechol estrogens are chemically reactive and potentially genotoxic/mutagenic, and it has been suggested that they play an important role in mediating hormonal carcinogenesis (18-20). In contrast, 2-methoxyestradiol, a non-polar endogenous E₂ metabolite with little binding affinity for human ER α and ER β , has a strong anti-proliferative, anti-angiogenic and apoptotic effect (7,21). It has been suggested that increased biosynthesis of this non-polar estrogen metabolite is highly beneficial for protection against estrogen-induced hormonal cancers (7,15).

A previous study showed that E₂ 15 α -hydroxylase activity, which catalyzes the formation of 15 α -OH-E₂ and 15 α -OH-E₃ (estetrol), was selectively elevated by 50- to 70-fold in a localized area of the uterine endometrium, where the imbedding of the fertilized ovum had taken place (22). Although the exact biological functions of the 15 α -hydroxylated estrogens are not clear at present, it is likely that the formation of 15 α -OH-E₂ and 15 α -OH-E₃ (estetrol) may be involved in the imbedding process. Similarly, the amount of 15 α -hydroxylated estrogens present in the urine of a late-stage pregnant woman can be used as a reliable



Comparison of daily urinary secretion (mean \pm SD) of endogenous estrogen metabolites during the pre-ovulatory phase, and post-ovulatory phase of a normal non-pregnant woman with that of five pregnant women.

Estrogen	Non-pregnant woman ($\mu\text{g}/24\text{-h urine}$)			Pregnant women ($\mu\text{g}/24\text{-h urine}$)
	Pre-ovulatory phase (days 6-10)	Ovulation (day 0)	Post-ovulatory phase (days 6-10)	
Estrone (E ₁)	6.2 \pm 3.9	30.8 \pm 15.6	16.2 \pm 12.4	49.1 \pm 37.8
17 β -Estradiol (E ₂)	0.9 \pm 0.8	3.8 \pm 1.9	1.6 \pm 0.2	26.5 \pm 11.3
2-Hydroxyestrone (2-OH-E ₁)	5.7 \pm 4.0	22.5 \pm 12.0	8.8 \pm 1.8	22.1 \pm 11.4
4-Hydroxyestrone (4-OH-E ₁)	0.7 \pm 0.4	2.2 \pm 0.2	1.1 \pm 0.3	2.4 \pm 0.8
16 α -Hydroxyestrone (16 α -OH-E ₁)	2.4 \pm 1.5	13.6 \pm 6.4	5.0 \pm 3.3	532.4 \pm 948.8
2-Methoxyestrone (2-MeO-E ₁)	2.4 \pm 0.2	0.5 \pm 0.8	0.8 \pm 0.4	6.9 \pm 3.4
2-Hydroxyestradiol (2-OH-E ₂)	0.8 \pm 0.4	1.8 \pm 1.2	1.2 \pm 0.3	3.4 \pm 3.6
4-Hydroxyestradiol (4-OH-E ₂)	ND	ND	ND	0.5 \pm 0.1
2-Methoxyestradiol (2-MeO-E ₂)	ND	ND	ND	11.5 \pm 14.5
Estriol (E ₃)	6.9 \pm 2.3	28.8 \pm 12.2	15.7 \pm 5.8	11,174.8 \pm 9,304.3
16-Epiestriol (16-epi-E ₃)	ND	ND	ND	562.3 \pm 626.3
17-Epiestriol (17-epi-E ₃)	ND	ND	ND	ND
16,17-Epiestriol (16,17-epi-E ₃)	ND	ND	ND	176.7 \pm 72.2
2-Hydroxyestriol (2-OH-E ₃)	ND	ND	ND	86.8 \pm 73.7
Estetrol (15 α -OH-E ₃)	ND	ND	ND	302.0 \pm 273.3

The collection of human urine samples was approved by the Institutional Review Board. Urinary estrogens were determined using the GC/MS method, as described below. An aliquot (1 ml) of the urine sample was transferred to a 1.5-ml microcentrifuge tube containing 200 μl 2 M Na₂AC buffer (pH 5.0), and the mixture was centrifuged at 14,000 rpm for 5 min. The supernatant (1 ml) was transferred to a small glass tube containing 20 μl of 0.5 $\mu\text{g}/\mu\text{l}$ E₂-D₂ (in pure ethanol) as the internal standard, and 75 μl of H-2 sulfatase as the enzyme for hydrolysis of estrogen conjugates. The reaction mixture was incubated at 37°C for 12 h. After incubation, the tubes were centrifuged at 4,000 rpm for 10 min, and the supernatants were transferred to another set of test tubes and extracted with 5 ml hexane/ethyl acetate (v:v, 3:2). The organic extracts were removed and dried under a stream of nitrogen gas. BSTFA (100 μl) was added for derivatization at 65°C for 1 h. The TMS derivatives of estrogen metabolites were detected using GC/MS. The GC/MS apparatus consisted of an Agilent 6890N GC with 7683 auto-sampler and an Agilent 5973 MS network, coupled with a HP-5MS capillary column. The front inlet temperature was 260°C, and the column flow rate was 1.0 ml/min. Oven temperatures were as follows: initial temperature was set at 180°C, then increased by 4°C/min to 260°C. This temperature was kept constant for 5 min, then further increased by 5°C/min to 300°C and kept constant for 5 min at 300°C (with the AUX temperature at 280°C). ND, the estrogen metabolite of interest was not detected.

indicator of fetal well-being, and in particular of fetal lung functions (23-27).

Third, we recently studied the binding affinity of a large number of endogenous estrogen derivatives for human ER α and ER β (5). We found that the major estrogens present in non-pregnant young women had a clearly different preference for the activation of ER α over ER β , compared to the estrogens present in pregnant women. Some of the relevant data are briefly discussed below.

We found that E₁ and 2-OH-E₁, two of the quantitatively major estrogens present in non-pregnant women, had a modest but significant preference for binding to human ER α over ER β (5). E₁ had a 3- to 4-fold higher preference for binding to human ER α than to ER β . Similarly, 2-OH-E₁ (the 2-hydroxylated metabolite of E₁) also had an \sim 4-fold preference for the activation of ER α over ER β . Notably, E₁ and 2-OH-E₁ had markedly lower binding affinity for human ER α and ER β compared to E₂. It is reasonable to believe that the relatively lower binding affinity of E₁ and 2-OH-E₁ is actually an advantage rather than a disadvantage, because they pose a

lower risk of causing over-stimulation of the ER α and ER β signaling systems *in vivo*.

On the other hand, E₃, the quantitatively predominant estrogen produced during human pregnancy, had a significant preference for binding to ER β over ER α (5). Although E₃ had a rather low binding affinity for human ER α compared to E₂ (RBA 11% of E₂), it retained a relatively high binding affinity for ER β (RBA 35% of E₂). Therefore, E₃ had an \sim 3 to 1 preference for binding to ER β over ER α . Similarly, 16 α -OH-E₁, another well-known hydroxylated metabolite of E₁ that is formed in very large quantities during pregnancy, had a higher binding preference for ER β than ER α when compared to E₁.

16,17-Epiestriol had a very low binding affinity for human ER α , but a preferential affinity for ER β ; the difference in binding affinity for ER β over ER α was 18-fold. Notably, this unique endogenous estrogen metabolite is usually undetectable in non-pregnant women, but is present at considerable levels during pregnancy (Table I).

In summary, it is evident that there is a distinct difference in the ratio and also intensity of ER α and ER β activation in

non-pregnant young women compared to pregnant ones. The major estrogens produced in non-pregnant women modestly favor the activation of ER α over ER β . However, during pregnancy there is a preponderance of activation of ER β over ER α exerted by various pregnancy estrogens, in particular by E $_3$, which is produced in unusually large quantities. This preferential activation of ER β is believed to play an indispensable role in the mediation of the various actions of the endogenous estrogens that are likely required for the development of the fetus, as well as for fulfilling other physiological functions related to pregnancy such as the suppression of autoimmune response against the fetus. These suggestions are in line with observations that ER β has a wide distribution in maternal reproductive and lymphatic organs in rats, as well as in various tissues in the fetus (28-30).

4. Biological activity of estrogens contained in Premarin

Premarin, the most commonly used HRT, contains a mixture of conjugated estrogens isolated from pregnant mare's urine. The major estrogens produced in a pregnant mare are quite different from those produced in a pregnant woman and do not contain E $_3$. However, they do contain a number of unique equine estrogens, many of which are basically not produced in humans. Our recent analysis showed that several of the equine estrogens contained in Premarin are functionally similar to the human pregnancy estrogen E $_3$ with respect to their preferential binding affinity for human ER β over ER α (5).

For example, while 17 β -dihydroequilenin had a low binding affinity for ER α (35% of E $_2$), it had a high binding affinity for ER β (RBA 100% of E $_2$). Equilin (i.e., 7-dehydro-E $_1$) had a decreased binding affinity for ER α compared to E $_1$ (RBA 40% of E $_1$) and a drastically increased affinity for ER β (RBA 631% of E $_1$). Similarly, *D*-equilenin had a much weaker binding affinity than E $_1$ for human ER α (RBA 20% of E $_1$), but its binding affinity for ER β was >3 times higher than that of E $_1$.

All together, it is evident that many of the equine estrogens contained in Premarin have a strong differential binding affinity for human ER β over ER α , which is very similar to the human pregnancy estrogen E $_3$.

5. Which estrogens are ideal for postmenopausal hormone replacement therapy?

The risks and benefits of Prempro (Premarin + progestin) in healthy postmenopausal women were evaluated by following a total of 16,608 women, aged 50-79 years (average age, 63 at study intake) (31). In this study, one branch followed patients who received either a combination of equine estrogens plus a progestin (8,506 women) or a placebo (8,102 women) for 5.2 years. It was found that there was an increased risk of breast cancer with the use of Prempro. The risk of coronary artery disease, strokes and pulmonary embolism was increased as well. The study found that the measured risks of this combination outweighed its measured benefits. For women aged 50-59, there was an observed trend towards a reduced risk of cardiovascular disease (relative risk, 0.56; 95% confidence interval, 0.30-1.03). Similarly, results from other studies suggested that when equine estrogens were administered orally,

liver functions were altered and the risk of blood clots was increased (32).

A previous study indicated that the adverse effects of oral conjugated equine estrogens may not be generalized to other estrogens (33). It appeared that while the conjugated equine estrogens were found to be associated with an increased risk of venous thrombosis, this risk was not associated with the use of esterified estrogen. Similarly, previous reports have suggested that the use of 17 α -ethynyl-estradiol contained in birth control pills appears to have different health effects on young women than does the use of equine estrogen-based HRT in postmenopausal women. It is not known whether the beneficial effect of 17 α -ethynyl-estradiol is due partly to its relatively higher preference for the human ER α over ER β as compared to equine estrogens.

It seems reasonable to suggest that an important empirical criterion that should be considered when an estrogen or a combination of estrogens is being evaluated for use in postmenopausal HRT is their ability to restore the hormonal environment to one found in normal non-pregnant young women, and not to one found in pregnant women. Since very different types of estrogens are produced in pregnant vs non-pregnant women and serve widely different physiological purposes, it is suggested that the use of endogenous estrogens found in non-pregnant young women will be more ideal for HRT than the use of estrogens predominantly produced during pregnancy. The former may include a combination of the sulfates of E $_1$ and 2-OH-E $_1$, and possibly other endogenous estrogens (such as the conjugates of 2-methoxyestrogens). The inclusion of methoxyestrogen sulfates in HRT may be beneficial because of 2-methoxyestradiol's strong anti-tumorigenic activity of (7,15). Given that many endogenous estrogens may have rather rapid metabolic disposition in the body, some other naturally-occurring or synthetic estrogens with longer half-lives can also provide a similar preferential activation of the ER α system as E $_1$ and may be useful as alternatives. For instance, since 17 α -E $_2$ has a similar ER-binding preference as E $_1$ but cannot be converted to E $_2$ by 17 β -hydroxysteroid dehydrogenase (17 β -HSD), the sulfate conjugates of 17 α -E $_2$ may serve as alternatives to E $_1$ -3-sulfate in order to achieve similar biological functions. In addition, our recent studies have shown that 17 α -E $_2$ has a strong protective effect against neuronal cell death both *in vitro* and *in vivo* (unpublished data).

This would be a good time to suggest that using sulfated estrogens for human HRT would be better than using their corresponding parent estrogens. The main reasons are, first, the sulfated estrogens are themselves inactive (with little or no binding affinity for human ER α and ER β) (5), but can be enzymatically hydrolyzed to release bioactive estrogens in a variety of tissues in the body. Previous studies have shown that the estrogen target organs, such as the breast and uterus, contain much higher levels of estrogen sulfatase activity than other tissues (34-37). Second, oral administration of estrogen sulfates would provide a natural cushion effect by avoiding unwanted over-stimulation of the ER systems throughout the body. Instead, they would usually only activate those target tissues or cells most in need of estrogenic stimulation. Here, it is also worth noting that several recent studies have shown that estrogen target cells can actively transport E $_1$ -3-sulfate




Figure 1. Differential activation of the human ER α and ER β in non-pregnant vs. pregnant women. In non-pregnant women, estrone (E₁) is believed to be the major circulating estrogen. 17 β -Estradiol (E₂) biosynthesized in the body is quickly converted to E₁ by the 17 β -hydroxysteroid dehydrogenase (17 β -HSD) present in various non-gonadal tissues, such as the liver. E₁ has rather low binding affinity for ER α and ER β compared to E₂, but has a preferential binding affinity for ER α over ER β . 2-OH-E₁ is the major metabolite of E₁ *in vivo*, and is also a very weak estrogen with a preference for ER α over ER β . It is therefore apparent that there is a preferential activation of the ER α system over the ER β system in non-pregnant women. In comparison, during pregnancy, the quantitatively predominant estrogens present in the circulation are estril (E₃) or 16 α -OH-E₁, which are either metabolically formed from 16 α -hydroxylation of endogenous estrogens (such as E₂ or E₁), or via other bio-synthetic pathways in the feto-placental unit. Both of these estrogens, which are formed in relatively small quantities in non-pregnant women, have a preferential binding affinity for ER β over ER α . Therefore, there is a clear difference in the ER activation profiles of non-pregnant vs. pregnant women. For hormone replacement therapy (HRT), the ideal situation is to mimic the hormonal status of non-pregnant healthy young women instead of that of pregnant ones. The current HRT, with its use of Premarin, largely mimics the hormonal conditions of a pregnant woman because, as our recent study (5) showed, many of the estrogens contained in Premarin (isolated from pregnant mare's urine) produce a preferential stimulation of human ER β over ER α .

into the cells (38,39). Moreover, these cells may selectively adjust their ability to actively transport E₁-3-sulfate into the cells to release biologically active estrogens depending on their hormonal needs. Theoretically, such a mechanism would offer certain degrees of target organ selectivity of estrogenic stimulation. Third, compared to estrogen glucuronides, estrogen sulfates are probably better because they usually have a lower clearance rate and a longer half-life (T_{1/2}) in humans, thereby making them pharmacologically more useful (40,41).

Based on the above discussion, it is suggested that the use of estrogens to produce a modest level of stimulation of both the ER α and ER β systems, with a slight preference for the ER α system, would be better for postmenopausal HRT than the use of estrogens that confer a predominant activation of the ER β system. It is apparent that Premarin, the most widely prescribed HRT, may not be the most suitable combination of estrogens for achieving this clinical purpose. Notably, while there is a considerable amount of E₁-3-sulfate contained in Premarin, which presumably is good for its intended purpose as an HRT, the fact is that it also contains many other very potent equine pregnancy estrogens which, jointly, result in a strong over-stimulation of the ER β system. Similarly, genistein, a potent

and preferential partial agonist of human ER β , would be even less suitable than Premarin for use as postmenopausal HRT because it would essentially produce a near selective ER β stimulation. This is in agreement with recent clinical observations, showing that the singular use of genistein is mostly ineffective as an HRT in postmenopausal women (42,43).

6. Concluding remarks

Until recently, the general scientific belief has been that all estrogens exert the same or highly similar pharmacological actions on a woman's body. When the oral tablet of Premarin was first approved by the U.S. Food and Drug Administration (FDA) for human use in 1942, its 0.625 mg dosage (still in use today) was actually assigned solely on the basis of its estrogenic potency in a rat bioassay that was found to be equivalent to 0.625 mg of sodium E₁-3-sulfate. This bioassay mostly measured the ER α -mediated uterotrophic activity. Even to this day, little is known about the precise hormonal strength of Premarin and each of the bioactive components for human ER α and ER β systems.

As discussed above, although E₂ is among the most potent endogenous estrogens and has almost equal binding affinity for human ER α and ER β , it is not one of the major estrogens present in women. In fact, E₁ or E₃, depending on the physiological conditions, are the quantitatively major estrogens present. Although their binding affinities for ER α and ER β are lower than those of E₂, they provide a differential activation of the ER α or ER β signaling system. Our recent study showed that endogenous estrogens (such as E₁ and 2-OH-E₁) present in non-pregnant women mainly activate the ER α system, whereas estrogens (such as E₃ and epi-E₃) present in pregnant women predominantly activate the ER β system. Therefore, the facile metabolic conversion of E₂ to E₁ or of E₂ to E₃ in women provides an important means of achieving differential activation of the ER α or ER β signaling system under different physiological conditions. This concept is summarized in Fig. 1.

It is reasonable to suggest that the estrogens most suitable for human HRT would be those that can mimic the physiological estrogenic stimulation of premenopausal non-pregnant women, and not that of pregnant women. Based on this new concept, it appears that naturally-occurring estrogens like E₁ and E₁-3-sulfate would be more suitable for use as postmenopausal HRT than Premarin, essentially composed of pregnancy estrogens (with a strong preference for ER β). It is apparent that a balanced activation of the ER α and ER β systems, with a modest preference for the ER α system, would be better for HRT, compared to estrogens that predominantly activate the ER β system. It is believed that an optimally-adjusted activation of the ER α and ER β signaling systems would help maximize the beneficial effects of HRT, and additionally minimize its untoward effects.

References

1. Nilsson S and Gustafsson JA: Estrogen receptor action. *Crit Rev Eukaryot Gene Expr* 12: 237-257, 2002.
2. Carpenter KD and Korach KS: Potential biological functions emerging from the different estrogen receptors. *Ann NY Acad Sci* 1092: 361-373, 2006.
3. Jordan VC: SERMs: meeting the promise of multifunctional medicines. *J Natl Cancer Inst* 99: 350-356, 2007.

4. Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. *Nat Rev Cancer* 7: 46-53, 2007.
5. Zhu BT, Han GZ, Shim JY, Wen Y and Jiang XR: Quantitative structure-activity relationship (QSAR) of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: insights into the structural determinants favoring a differential subtype binding. *Endocrinology* 147: 4132-4150, 2006.
6. Zhu BT and Conney AH: Functional role of estrogen metabolism in target cells: review and perspectives. *Carcinogenesis* 19: 1-27, 1998.
7. Zhu BT and Conney AH: Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? *Cancer Res* 58: 2269-2277, 1998.
8. Weisz J: Metabolism of estrogens by target cells: diversification and amplification of hormone action and the catechol estrogen hypothesis. In: *New Biology of Steroid Hormones*. Hochberg RB and Naftolin F (eds). Raven Press, New York, pp101-112, 1991.
9. Fotsis T and Adlercreutz H: The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS-I. Quantitation of estrogens after initial hydrolysis of conjugates. *J Steroid Biochem* 28: 203-213, 1987.
10. Fotsis T: The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS-II. Fractionation and quantitation of the main groups of estrogen conjugates. *J Steroid Biochem* 28: 215-226, 1987.
11. Lee AJ, Cai MX, Thomas PE, Conney AH and Zhu BT: Characterization of the oxidative metabolites of 17 β -estradiol and estrone formed by fifteen selectively expressed human cytochrome P450 isoforms. *Endocrinology* 144: 3382-3398, 2003.
12. Lee AJ, Kosh JW, Conney AH and Zhu BT: Characterization of the NADPH-dependent metabolism of 17 β -estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. *J Pharmacol Exp Ther* 298: 420-432, 2001.
13. Lee AJ, Mills LH, Kosh JW, Conney AH and Zhu BT: NADPH-dependent metabolism of estrone by human liver microsomes. *J Pharmacol Exp Ther* 300: 838-849, 2002.
14. Zhu BT and Lee AJ: NADPH-dependent metabolism of 17 β -estradiol and estrone to polar and nonpolar metabolites by human tissues and cytochrome P450 isoforms. *Steroids* 70: 225-244, 2005.
15. Zhu BT: Catechol-*O*-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: Importance in pathophysiology and pathogenesis. *Curr Drug Metab* 3: 321-349, 2002.
16. Liu D and Bachmann KA: An investigation of the relationship between estrogen, estrogen metabolites and blood cholesterol levels in ovariectomized rats. *J Pharmacol Exp Ther* 286: 561-568, 1998.
17. Ball P and Knuppen R: Catecholestrogens (2- and 4-hydroxy-oestrogens): chemistry, biogenesis, metabolism, occurrence and physiological significance. *Acta Endocrinol* 232: 1-127, 1980.
18. Liehr JG: Is estradiol a genotoxic mutagenic carcinogen? *Endocr Rev* 21: 40-54, 2000.
19. Cavalieri E, Frenkel K, Liehr JG, Rogan E and Roy D: Estrogens as endogenous genotoxic agents - DNA adducts and mutations. *J Natl Cancer Inst Monogr* 27: 75-93, 2000.
20. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. *N Engl J Med* 354: 270-282, 2006.
21. Sutherland TE, Anderson RL, Hughes RA, Altmann E, Schuliga M, Ziogas J and Stewart AG: 2-Methoxyestradiol - a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. *Drug Discov Today* 12: 577-584, 2007.
22. Chakraborty C, Davis DL and Dey SK: Estradiol-15 α -hydroxylation: a new avenue of estrogen metabolism in peri-implantation pig blastocysts. *J Steroid Biochem* 35: 209-218, 1990.
23. Tulchinsky D, Frigoletto FD Jr, Ryan KJ and Fishman J: Plasma estretol as an index of fetal well-being. *J Clin Endocrinol Metab* 40: 560-567, 1975.
24. Kundu N and Grant M: Radioimmunoassay of 15 α -hydroxy-estriol (estretol) in pregnancy serum. *Steroids* 27: 785-796, 1976.
25. Notation AD and Tagatz GE: Unconjugated estriol and 15 α -hydroxyestriol in complicated pregnancies. *Am J Obstet Gynecol* 128: 747-756, 1977.
26. Taylor NF and Schackleton CHL: 15 α -Hydroxyestriol and other polar oestrogens in pregnancy monitoring - A review. *Ann Clin Biochem* 15: 1-11, 1978.
27. Kunda N, Wachs M, Iverson G and Petersen LP: Comparison of serum unconjugated estriol and estretol in normal and complicated pregnancies. *Obstet Gynecol* 58: 276-281, 1981.
28. Saunders FJ: Effects of sex steroids and related compounds on pregnancy and on development of the young. *Physiol Rev* 48: 601-643, 1968.
29. Hewitt SC and Korach KS: Oestrogen receptor knockout mice: Roles for oestrogen receptors α and β in reproductive tissues. *Reproduction* 125: 143-149, 2003.
30. Lemmen JG, Broekhof JL, Kuiper GG, Gustafsson J-Å, van der Saag PT and van der Burg B: Expression of estrogen receptor α and β during mouse embryogenesis. *Mech Dev* 81: 163-167, 1999.
31. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J and Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 288: 321-333, 2002.
32. Scarabin PY, Oger E, Plu-Bureau G and Estrogen and Thromboembolism Risk Study Group: Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 362: 428-432, 2003.
33. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR and Psaty BM: Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. *JAMA* 292: 1581-1587, 2004.
34. Hobbirk R: Steroid sulfotransferases and steroid sulfate sulfatases: Characteristics and biological roles. *Can J Biochem Cell Biol* 63: 1127-1144, 1985.
35. Santner SJ, Feil PD and Santen RJ: *In situ* estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. *J Clin Endocrinol Metab* 59: 29-33, 1984.
36. MacIndoe JH, Woods G, Jeffries L and Hinkhouse M: The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. *Endocrinology* 123: 1281-1287, 1988.
37. Pasqualini JR, Gelly C, Nguyen B-L and Vella C: Importance of estrogen sulfates in breast cancer. *J Steroid Biochem* 34: 155-163, 1989.
38. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B and Sasano H: Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. *Cancer Res* 66: 535-542, 2006.
39. Nozawa T, Suzuki M, Takahashi K, Yabuuchi H, Maeda T, Tsuji A and Tamai I: Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. *J Pharmacol Exp Ther* 311: 1032-1037, 2004.
40. Twombly GH and Levitz M: Metabolism of estrone-C¹⁴-16 sulfate in women. *Am J Obstet Gynecol* 80: 889-898, 1960.
41. Ruder HJ, Loriaux L and Lipsett MB: Estrone sulfate: production rate and metabolism in man. *J Clin Invest* 51: 1020-1033, 1972.
42. Fitzpatrick LA: Soy isoflavones: Hope or hype? *Maturitas* 44 (Suppl 1): 21-29, 2003.
43. Rozman KK, Bhatia J, Calafat AM, Chambers C, Culty M, Etzel RA, Flaws JA, Hansen DK, Hoyer PB, Jeffery EH, Kesner JS, Marty S, Thomas JA and Umbach D: NTP-CERHR expert panel report on the reproductive and developmental toxicity of genistein. *Birth Defects Res B Dev Reprod Toxicol* 77: 485-638, 2006.